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Prostate cancer continues to be a major cause of morbidity and mortality in men around the
world. The field of prostate cancer research continues to be hindered by the lack of relevant
preclinical models to study tumorigenesis and to further development of effective prevention
and therapeutic strategies. The Prostate Cancer Foundation held a Prostate Cancer Models
Working Group (PCMWG) Summit on August 6th and 7th, 2007 to address these issues. The
PCMWG reviewed the state of prostate cancer preclinical models and identified the current
limitations of cell line, xenograft and genetically engineeredmousemodels that have hampered
the transition of scientific findings from these models to human clinical trials. In addition the
PCMWG identified administrative issues that inhibit the exchange of models and impede
greater interactions between academic centers and these centers with industry. The PCMWG
identified potential solutions for discovery bottlenecks that include: (1) insufficient number of
models with insufficient molecular and biologic diversity to reflect human cancer, (2) a lack of
understanding of themolecular events that define tumorigenesis, (3) a lack of tools for studying
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tumor–host interactions, (4) difficulty in accessing model systems across institutions, and
(5) addressing why preclinical studies appear not to be predictive of human clinical trials. It
should be possible to apply the knowledge gainedmolecular and epigenetic studies to develop
new cell lines and models that mimic progressive and fatal prostate cancer and ultimately
improve interventions. Prostate 68: 629–639, 2008. # 2008 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer continues to be a major cause of
morbidity and mortality, accounting for 27,000 deaths
in 2007 in the United States alone [1]. While discoveries
continue to be made regarding the etiology of this dis-
ease, the field of prostate cancer research continues to
be hampered by the lack of relevant preclinical models
to study tumorigenesis and to develop effective
prevention and therapeutic interventions. To address
this, the Prostate Cancer Foundation held a Prostate
Cancer Models Working Group (PCMWG) Summit on
August 6th and 7th, 2007. The charge of the PCMWG
was to review the state of the art of prostate cancer
preclinical models and identify the current limitations
of cell line, xenograft, and genetically engineered
mouse (GEM) models that have hampered the tran-
sition of scientific findings from thesemodels to human
clinical trials. In addition the PCMWG identified
administrative issues that inhibit the exchange of
models and impede greater interactions between
academic centers and these centers with industry.
While an incomplete understanding of the biologyof
human prostate cancer complicates the development of
relevant model systems that mimic the human disease,
many genetic changes have been associated with
prostate cancer that appear to correlate with micro-
scopic changes in cell structure and gland histology
(Fig. 1) [2–15]. Early prostate tumorigenesis appears
to be associated with a dysplasia that starts with
proliferative inflammatory atrophy (PIA) which may
progress to prostatic intraepithelial neoplasia (PIN)
which may progress to carcinoma [4]. These early
lesions may be initiated by inflammation that occurs
with exposure to different infectious agents and/or
carcinogens [2–8]. As premalignant lesions progress to
primary cancer, to metastatic cancer, and to hormone
refractory cancer after hormonal treatment, genetic
damage continues to accumulatewithin the cancer cells
[2–15]. The most effective models are, and will be, the
ones that can be used to mimic the changes human
disease, can be utilized to ask questions that explain
observed phenomena of the human condition, and
would be predictive for therapeutic efficacy. The field
also needs to continually incorporate discoveries in the






Currently, preclinical models of prostate cancer in
major use include those derived from rat, canine,
mouse, and human sources. The Dunning rat model,
although not as widely used presently as it has been in
the past, continues to be the only spontaneously
derived prostate cancer model with multiple sublines
that metastasize quickly and reproducibly to multiple
organs (Fig. 2) [16–20]. The canine ACE-1 grows as a
cell line and as a xenograft and was derived from a
primary adenocarcinoma. When implanted in bone, it
demonstrates an osteoblastic pattern [21]. Most labo-
ratories are now utilizing human cell lines and/or
xenografts or genetically engineered models (GEM) in
mice for preclinical prostate studies.
There have been several excellent reviews of the
available human prostate cancer cells [22–26]. Table I
includes the top 10 most cited in the literature by
PUBMED search. By far, the classic three cell lines, PC-
3, LNCaP, and DU145, are the most widely used, each
with thousands of studies published. Each of the other
human cell lines have less than 200 citations. Despite
the use of all of these models, it is clear that a basic
understanding and characterization of existing models
andhow their properties compare to thehumandisease
is lacking andneeded for growth in the field. It is critical
that researchers understand the properties of cell lines
on a general level, but also to use the correct cell line/
model for the scientific problem that they are studying.
Thus, while the androgen receptor (AR) status of a cell
line is generally known, the growth factor receptor
status and signal transduction pathways are also
important to delineate prior to initiating studies. The
PC-3 and LNCaP cell lines each have multiple sublines
associatedwith them, however, ingeneral, these are not
fully genetically and phenotypically characterized, nor
is there a method for standardization (Figs. 3 and 4)
[22]. It is possible thatmany of the deficiencies that exist
in the preclinical models could be addressed simply
through better genetic and phenotypic characterization
of the models already in existence. For example, each
cell line should have published chromosomal analyses,
state of growth factor and signal transduction path-
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ways, and sensitivities to chemotherapies, hormonal
therapies, and radiation. Each cell line should be
characterized as to how it grows in vitro, and in vivo
after being implanted/injected within orthotopic,
subcutaneous, lymphatic, intra-osseous, intravenous,
and intra-cardiac sites. However, as biological models
evolve after serial passages in vitro and in vivo, caution
should be taken in the interpretation of published
studies and characterization of key features may be
advisable in each lab prior to the use of the model of
interest. Each publication with a prostate cancer model
needs to standardize the models used with existent
molecular/phenotypic data.
Summary of potential solutions.
(1) Create a repository of early passage (within 5–
10 passages) of well-characterized cell lines and
xenografts at the genetic and biochemical levels.
This should include chromosomal analysis as
well as gene expression data from in vitro and
xenograft data. Data should include growth factor
receptor expression as well as the common signal
transduction pathways. Gene expression data on
a minimal subset of biomarker genes (e.g. AR,
PSA, PAP, K8, K18, Vimentin, NSE) on the existing
cell lines and xenografts could be deposited in a
The Prostate
Fig. 1. Histologic andmolecular changes associatedwithprostate tumorigenesis.Formore information, seeRefs. [21^34].PIA, proliferative
inflammatory atrophy; RNASEL, 20 -50 -oligoadenylate-dependent RNase L; AMACR, a-methylacyl-coenzyme A racemase; EZH2, enhancer of
zestehomolog2;PcG,polycombgroup.Originalmagnification100.TakenfromTaichmanetal. [1].
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public domain website, which can be updated by
researchers. This information could be helpful to
gain a better understanding on genetic drifts of
existing models and to provide a context of
research findings from different groups.
(2) Characterization of how each cell line/xenograft
grows after intra-cardiac and intravenous injection
as well as after implantation at subcutaneous,
orthotopic, lymphatic, and osseous sites. The
lack of cell lines/xenografts which spontaneously
The Prostate
TABLE I. Prostate CancerCell Lines
Species Model Source
Androgen
receptor status Other properties
Canine Ace-1 Cell line from primary
adenocarcinoma
AR CyK8, 18þ, vimentin þ
Rat Dunning Spontaneous from primary
adenocarcinoma




PC-3 Cell line from bone metastasis  PSA, negative for p53
LNCaP Cell line from lymph node metastasis Mutated AR PSAþ, CK8, 18þ; WT p53
DU145 Cell line from dural metastasis  PSA, PAPþ, CK 7, 8, 18,
19þ, mutated p53
CWR22rv1 Gleason 9 TURP þ PSAþ, 22Rv1 cells express
CK-8, 18þ, mutated p53
LuCaP 23 Lymph node metastasis þ PSA, PAPþ
LuCaP 35 Xenograft from lymph node
metastasis
þ, WT AR PSAþ
MDA PCa 2a Cell line from bone metastasis Mutated AR PSAþ; WT p53, CK 5, 8, 18þ
VCaP Cell line from bone metastasis þ, WT AR PSAþ, PAPþ, PSMAþCK 8,
18 þ, mutated p53
LAPC-4 Cell line from lymph node metastasis þ PSAþ, PSCAþ, PSMAþ,
CK 8, 18þ Mutated p53
PC-82 Primary prostate, cribiform pattern þ PAPþ
PreC Non-immortalized prostate epithelial
cells
AR PSA-, p63þ, CK 8, 18þ
RWPE Immortalized prostate epithelial cells þ PSAþ, CK 8, 18þ
Fig. 2. The developmentof theDunningratprostate adenocarcinoma cell lines.A: Schematic of the developmentof theDunning sub lines.
B:Characteristics of theDunning sublines. [Personalcommunication, J.Isaacs].
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Fig. 3. Thedevelopmentof theLNCaPprostateadenocarcinomacell sublines.TakenfromSobelandSadar [22].
Fig. 4. Thedevelopmentof thePC-3prostateadenocarcinomacell lines.TakenfromSobelandSadar [22].
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metastasize in a reproducible manner continues
to be a major problem for the field. How each of
the cell lines behaves when injected at various
primary and metastatic sites and in hosts with
various genetic backgrounds has not been well
explored. How each of the cell lines may under-
go genetic drifts when passaged in culture or im-
plant in mice under various hormonal conditions
or cell culture media should be better defined.
(3) Characterization and standard reporting of how
each cell line/xenograft responds to radiation,
chemotherapies, and targeted therapies. The ther-
apeutic dose response curves for each cell line
in vitro and in vivo should be readily accessible so
investigators can compare their data with pub-
lished standards. This would allow comparison of
agents and demonstrate that controls were com-
parable across different laboratories and between
different experiments.
(4) Placement of all data in a public domain website so
that it is accessible to the field. All of the data
generated on the cell lines should be placed in a
website that is continually updated. Expression
array data could be maintained in an ‘‘Oncomine’’
format [27]. Since there is no centralized and
standardized quality assurance of cell lines to
make sure genetic drift has not occurred, inves-
tigators could determine if the model that they are
using has ‘‘drifted’’ from those previously pub-
lished by placing appropriate control data on the
website.
(5) Generation of new cell lines. It remains unclear
why prostate cancer cells are so difficult to isolate
and successfully transfer to tissue culture as
compared to other disease sites. Multiple inves-
tigators have utilized varying methods, including
co-culture, to increase the number of available cell
lines. Immortalization with hTERT or other meth-
ods may be needed to increase the number of
human models, especially those derived from
primary tumors. The NCI 60 panel has too few
prostate cancer cell lines and the prostate cancer
cell lines it contains are biologically suboptimal. As
new cell lines are generated, they should be added
to the NCI panel.
(6) Deficiencies in anatomic, functional, andmetabolic
imaging complicate monitoring of progression in
xenograft models. Knowledge on the limitations of
different imaging modalities and relevant appli-
cation to current models is lacking. The under-
standing of cancer progression and therapeutics
can benefit greatly from novel imaging tracers or
innovative imaging reporter systems that can
reveal the activities of specific molecular pathway
in the living subjects.
Bottleneck:TheMolecular EventsThatDef|ne
ProstateTumorigenesis RemainUnclear
GEM models are helping define the molecular
events of prostate tumorigenesis (Fig. 5, Table II) [28–
31]. GEM models break into two broad areas, those
generated by overexpression of an oncogene with a
prostate specific promoter and those with targeted
deletion of specific genes. The transgenic mousemodel
of prostate (TRAMP) model is currently the most
widely used, and best characterized of all of these
models (http://thegreenberglab.fhcrc.org/) [32–34].
The autochthonous TRAMP utilizes a transgene speci-
fically overexpressed in the epithelial cells of the
prostate which results in the development of prostate
cancers in a manner that mimics the histopathology of
human PCa development (http://thegreenberglab.
fhcrc.org/). The mice exhibit progressive stages of
prostate cancer ranging from mild to severe prostatic
hyperplasia with cribriform structures and focal
adenocarcinoma and seminal vesicle invasion to occa-
sional metastatic spread to the lymph nodes, lung, and
bone. Since the development of TRAMP, several other
transgenic models have become available [28–31].
Several murine models generated by disruption
or overexpression of genes in the prostate develop
premalignant as well as malignant lesions. The best
characterized of these models is the loss of the tumor
suppressor gene phosphatase and tensin homologue
(PTEN) [35–37]. The lipid phosphatase PTEN, acts
as a tumor suppressor gene by acting as a negative
regulator of the phosphatidylinositol 3-kinase/AKT
pathway. Approximately 70% of primary prostate
cancers exhibit a loss of at least one PTEN allele and
loss of both alleles is associated with advanced disease
[35,36]. In mice, loss of one allele of PTEN is associated
with the development of high-grade PIN and condi-
tional loss of PTEN results in invasive prostate cancer
that metastasizes to lymph nodes and lung in some
animals [38]. Combining PTEN loss with other genetic
abnormalities observed in human prostate cancers has
led to several models of disease [39–42]. Mice nullizy-
gous for PTEN and p53 in the prostate develop
aggressive prostate cancer [39]. NKX3.1 encodes a
homeodomain transcription factor located on a region
of human chromosome 8p21 that is frequently deleted
in prostatic intraepithelial neoplasia (PIN) as well as
prostate cancer (reviewed [40–43]). Loss of NKX3.1
function in mice leads to PIN [43]. Nkx3.1;Pten
compound mutant mice develop androgen-independ-
ent prostate cancer that retains wild-type AR expres-
sion and function [40–42]. Thesemice, aswell as others,
have given the field powerful new tools to understand
prostate cancer biology. However, biology, however,
their usefulness in the areas of prevention and
The Prostate
634 Pienta et al.
therapeutic discovery remain largely unexplored, in
large part because of the time it takes for these models
to generate cancers and the expense of generation and
maintenance, but also because of uncertainty about
their predictive value for these interventions in
humans. Moreover, GEMmodels also preclude testing
of human-specific diagnostic or therapeutic reagents
(e.g., antibodies).
Summary of potential solutions
(1) Increase the number and sophistication of GEM
models to better mimic human disease progres-
sion. While the current GEM models have given
increasing insight into the molecular events that
contribute to prostate tumorigenesis, additional
models that target new oncogenic events, that
modify the tumor ecology (e.g., stroma, cytokines),
and that combine mutations will add significantly
to the knowledge base.
(2) Better define the biology of the mouse prostate as
compared to the human prostate. The mouse
prostate differs significantly from the human.
The human prostate is a discrete, encapsulated
organ composed of central (25%), transitional (5%),
and peripheral zones (70%). The mouse prostate is
not a discrete unit and is composed of four-paired
lobes; anterior, dorsal, lateral, and ventral without
a discrete capsule. Adding to these differences in
microscopic and gross anatomy is the fact that the
mouse prostate does not spontaneously develop
prostate cancer and does not make PSA. These
differences in mouse and human prostates should
be well characterized at the genetic and molecular
levels so as to make interpretation of results
derived from models as meaningful as possible.
(3) Developmore cell lines fromGEMmodels to allow
more rapid study of prostate cancer cell lines in
immunocompetent hosts. One of the drawbacks to
GEM models is that they generally take months
to develop and therefore, their use for testing
therapeutic interventions has been limited. GEM
models, do however, allow the testing of agents in
immunocompetent hosts. One way to speed agent
The Prostate
Fig. 5. Diagrammaticsummaryof theonsetandprogressionofprostatecancerresulting fromone,two,ormultiplegeneticdisruptions.Taken
fromKasper [31].
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testing in these models is to develop more cell lines
from the GEM models to allow autochthonous
xenograft testing.
Bottleneck: ALackof Tools for Studying
Tumor^Host Interactions
Prostate cancer can no longer be considered a
disease of a single cell type but rather must be viewed
as a complex system of epithelial cells that exhibit
dysregulated growth within the framework of a
microenvironment of multiple cells supporting that
growth as well as the macroenvironment of the host
with a unique genotype and immune system. Collec-
tively, these components constitute an ecosystem that
selects for the biological characteristics of the tumor.
Further research is needed to better define these
interactions, many of which are potential targets for
therapy. While no model fully mimics human host
biology and the human tumor microenvironment, in
vivo models can be utilized to study specific compo-
nents of tumor initiation andprogression, including the
interactions of prostate cancer cells with stroma and
with bone bearing human xenografts. Development of
future mouse models with high frequencies of sponta-
neous prostate cancer bone metastasis will prove to be
highly attractive.
Summary of potential solutions
(1) Development of better mouse models that allow
studying host immune response to prostate cancer.
Continual development of more relevant models
of tumor–immune system interactions is desper-
ately needed.
(2) Generation of promoters that can regulate gene
expression in stroma and other sites of interaction,
such as bone. This is critical for generating relevant
animal models both utilizing xenografts as well as
GEM models.
(3) Generation of more stromal cell lines. These lines
should include fibroblasts and endothelial cells
from prostate as well as common metastatic sites,
including bone, liver, and lymph node. Other lines
would include osteoclasts, osteoblasts, and nerve
cells. The interaction of prostate cancer cells with
the hematopoetic progenitor cells of the bone
marrow should be explored.
(4) Characterization of xenografts that are generated
with stromal cells as well as tumor cells. Data
suggest that tumor cells react differently to
therapy when they are in contact with different
substrata as well as in contact with different cell
types. Relevant models should be generated that
include combining tumor cells with as many
The Prostate
TABLE II. ASummaryofMurineModels of Prostate Cancer
Hyperplasia/PIN only
Invasive carcinoma
without metastasis Metastatic carcinoma
Nkx3.1 / ARR2PB-c Myc TRAMP
PSACre; NKx3.1 loxP/loxP PB-c-Myc C3(1)-Tag
PB-AR Nkx3.1/ and Pten þ/ PSP94-Tag
MPAKT LADY (LPB-Tag) gp91-phox-Tag
C(3)1-c-Myc Pten hy/
PB-Ras LADY (LPB-Tag, line 12T-10)
PBCre4; RXRa loxP/loxP PBCre4; PTEN loxP/loxP








Adapted from Abdulkadir and Kim [29].
AR, androgen receptor; ARR2PBi, androgen-responsive regions 2 probasin bigenic promoter;
caFGFR, constitutively active fibroblast growth receptor mutant; FGF, fibroblast growth factor;
FGFR, fibroblast growth factor receptor; gp, glycoprotein; hy, hypomorph; PB, probasin promoter;
PBCre, probasin promoter cAMP responseelement; phox, phox homology; PIN, prostatic
intraepithelial neoplasia; PSA, prostate-specific antigen; Pten, phosphatase and tensin homolog;
rPRL, rat prolactin; RXR, retinold X receptor; SKP, S-phase kinase-associated protein; TRAMP,
transgenic mouse model of prostate.
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normal cell types as possible. It is well recognized
that spontaneous metastasis of xenografts is a
deficient property of prostate cancer models and
that this complicates attempts to study the process
of metastasis in vivo. It is possible that the creation
of more complex tumor—microenvironment mod-
els will facilitate spontaneous metastasis in vivo.
Bottleneck: Access toModel Systems
Across Institutions
Collaboration between different academic laborato-
ries as well as between academia and industry is
complicated by multiple factors. Models held by the
ATCC as well as different mouse distribution centers
often have demands that exceed their capacity
for timely response. Collaboration between laborato-
ries, whether academic or industrial, is further compli-
cated by the process of materials transfer agreements.
These agreements also make it hard to freely test
proprietary compounds in models.
Summary of potential solutions
(1) Create a virtual systematic database for reagents,
methods, characteristics, and controls for cell lines,
xenograft models, and GEM models. This type
of database would allow informed experiment
design and model use and would increase the
quality of research in the field.
(2) Create a central organizational structure for MTAs
between individual laboratories as well as between
investigators and industry. This may help facilitate
the movement of materials between universities as
well as simply licensing.
Bottleneck:Preclinical StudiesAppearNottobe
Predictive ofHumanClinical Trials
The conundrum of why preclinical models have not
been more predictive of results in human studies is the
result of inadequate models, inappropriate use of the
models that are available, and subsequent design of
clinical trials that do not mirror the preclinical model
testing.
Summary of potential solutions
(1) Design of appropriate preclinical studies that
utilize the appropriate agent doses, pharmacoki-
netic and pharmacodynamic parameters to take
into account the differences in metabolism
between mouse and human. Preclinical studies
should be done that mirror what can be done in
patients. The lack of clinical feedback in the design
of many preclinical studies complicates the trans-
lation of findings to first in man trials.
(2) Design human clinical trials that mimic the
preclinical trials in animals. While it is true many
preclinical studies of drug efficacy are designed
without appropriate thought of how the agents can
be given in humans, it is also true that the design of
clinical trials rarely takes into account how the
preclinical testing was accomplished.
CONCLUSION
The genetically engineered, xenograft and cell
culture models of prostate cancer have contributed to
multiple important discoveries in the field. No single
model accurately represents all the molecular or
cellular features of prostate cancer as it develops from
normal prostate and progresses tometastatic, hormone
refractory disease. Given the vast amount of informa-
tion gained through genomic, proteomic, and epige-
netic studies it should be possible to apply this
knowledge to develop a new cell lines and models that
mimic progressive and fatal prostate cancer and
ultimately improve interventions.
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